A Phase I Open-Label Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-hodgkin Lymphoma, Unspecified
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically documented lymphomas expected to express CD19 and CD20 including: Grade 1-3b FL; marginal zone lymphoma; transformed indolent NHL; Richter transformation with DLBCL morphology and with absolute lymphocyte count <5000/µL; DLBCL; primary mediastinal B-cell lymphoma; small lymphocytic lymphoma; or mantle cell lymphoma. 2) Relapsed/refractory disease following prior systemic immunochemotherapy regimen who have no available curative treatment options and who have limited prognosis (<2 years’ survival) with currently available therapies. 3) At least one bi-dimensionally measurable lesion, e.g., nodal lesion >1.5 cm in longest dimension or extra-nodal lesion >1.0 cm in longest dimension by computed tomography (CT) scan.

You may not be eligible for this study if the following are true:

  • 1) Females who are pregnant or breastfeeding. 2) Eastern Cooperative Oncology Group (ECOG) Performance Status =2. 3) Receipt of any biological therapy, chemotherapy, or radiation (except palliative radiation, rituximab, or obinutuzumab) within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to Day 1. 4) Receipt of an allograft organ transplant.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.